Advance the non-clinical and early clinical development of DNDI-0690, a selected nitroimidazole for the treatment of visceral leishmaniasis and possibly cutaneous leishmaniasis
current phase of drug development
updated 1 Mar 2022
DNDI-0690 is a nitroimidazole derivative that has shown good to excellent activity in vitro against strains of Leishmania that cause both visceral leishmaniasis and cutaneous leishmaniasis.
DNDI-0690 was identified from a library of approximately 70 nitroimidazole compounds that DNDi accessed through an agreement with the TB Alliance. While the TB Alliance investigated this class of compounds for potential TB therapies, the agreement enabled DNDi to test the compounds for potential anti-leishmanial activity.
Following its nomination as a pre-clinical candidate in September 2015, DNDI-0690 was profiled in vitro against strains of Leishmania that cause cutaneous leishmaniasis at the London School of Hygiene & Tropical Medicine and the Walter Reed Army Institute of Research.
Pre-clinical work to prepare for first-in-human studies was completed in 2019. A first Phase I study ran through early 2020 and demonstrated a favourable safety profile for single dose administration in healthy adults.
Get our latest news, personal stories, research articles, and job opportunities.